Filing summary
Entity and period: The supplied filing is Leap Therapeutics, Inc.’s Form 10-K for the fiscal year ended December 31, 2022, filed March 24, 2023. This does not match the request metadata identifying Cypherpunk Technologies Inc. It reports annual results, not a standalone 2022 fourth quarter.
Business context
Leap is a clinical-stage oncology biotechnology company with no approved products and no product-sale revenue. Its lead candidate, DKN-01, is being studied in esophagogastric, gynecologic and colorectal cancers. The filing also describes FL-301 as a clinical-stage candidate and FL-302 and FL-501 as preclinical programs; these programs came with the January 2023 acquisition of Flame Biosciences, after the reporting year.
Financial performance and position
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | No license revenue; no product-sale revenue | $1.5 million license revenue; no product-sale revenue |
| Research and development expense | $45.0 million | $32.2 million |
| General and administrative expense | $11.8 million | $10.8 million |
| Net loss | $54.6 million | $40.6 million |
| Net loss per share, basic and diluted | $0.48 | $0.47 |
| Cash used in operating activities | $49.0 million | $35.2 million |
| Cash and cash equivalents at year-end | $65.5 million | $114.9 million |
R&D expense rose $12.8 million, mainly from clinical-material manufacturing, trial costs and increased R&D staffing. The loss widened by $14.0 million, reflecting higher operating expenses and the absence of the prior-year $1.5 million license revenue. Interest income increased to $0.9 million from an immaterial amount; Australian R&D incentive income was $2.1 million versus $1.2 million.
Cash declined by $49.4 million during 2022. The company reported $70.4 million in total assets, $11.5 million in total liabilities and $58.9 million in stockholders’ equity at year-end. The filing reports lease liabilities but no material borrowings or debt balance. No gross margin or operating margin is meaningful for a company with no product sales.
Liquidity, changes and notable items
- Management expected year-end cash plus approximately $50 million acquired with Flame to fund operations for at least 12 months from the filing/financial-statement issuance date. This is an estimate based on assumptions; additional funding may be needed.
- Flame was acquired on January 17, 2023, after year-end. Leap issued approximately 19.8 million common shares and 136,833 Series X preferred shares, each convertible into 1,000 common shares with stockholder approval. Failure to obtain approval within six months could allow holders to require cash settlement at fair value, which management said could materially harm liquidity.
- In March 2023, BeiGene declined its option to license DKN-01 in specified Asian-Pacific territories. The companies planned to continue their clinical collaboration, including BeiGene’s supply of tislelizumab for the DisTinGuish trial.
- Leap received a Nasdaq notice in November 2022 for a bid price below $1.00, with a compliance period through May 1, 2023. The filing provides no assurance the company would regain compliance.
- There were $4.7 million of non-cancellable DKN-01 manufacturing commitments at year-end. The company reported no material legal proceedings.
Outlook, clinical developments and risks
- Management expected continued significant operating losses and higher R&D spending. No revenue, profitability or product-launch guidance was provided.
- Enrollment in the randomized, approximately 160-patient Part C of the DKN-01 DisTinGuish study began in October 2022. Management anticipated initial response-rate data around year-end 2023 or early 2024, with PFS data in 2024. These are forward-looking expectations, not guarantees.
- For DKN-01 in colorectal cancer, the company expected initial Part A DeFianCe data in mid-2023. For FL-301, it expected initial clinical data from the China trial later in 2023 or early 2024.
- Reported DKN-01 results were preliminary and largely from small, open-label studies; the filing cautions that early results may not predict results in larger controlled trials. Neither DKN-01 nor FL-301 was FDA-approved or submitted for FDA approval.
- Key risks include clinical and regulatory failure or delay, trial enrollment and manufacturing constraints, dependence on CROs and partners (including BeiGene and NovaRock), competition, financing needs, potential Series X cash redemption, dilution, and market/economic disruption. Management also cited inflation, COVID-19, global conflict and supply-chain issues.
The independent auditor issued an unqualified opinion on the financial statements. Management stated that disclosure controls and internal control over financial reporting were effective as of December 31, 2022; the auditor did not attest to internal-control effectiveness.
Important facts for investors to verify
- Confirm the filing belongs to the intended issuer: the request names Cypherpunk Technologies Inc., but this document is Leap Therapeutics’ 10-K.
- Review the full financial statements and subsequent filings for cash use, post-acquisition liquidity, and the assumptions behind the stated 12-month runway.
- Check the status and terms of the Series X conversion vote, including any cash-settlement exposure and resulting dilution.
- Verify current Nasdaq listing compliance and the status of any financing or share-registration arrangements related to the Flame acquisition.
- Track BeiGene’s tislelizumab supply and the timing, enrollment and results of the DisTinGuish, DeFianCe and FL-301 studies.